NO981454L - Anti-FAS-antistoffer - Google Patents

Anti-FAS-antistoffer

Info

Publication number
NO981454L
NO981454L NO981454A NO981454A NO981454L NO 981454 L NO981454 L NO 981454L NO 981454 A NO981454 A NO 981454A NO 981454 A NO981454 A NO 981454A NO 981454 L NO981454 L NO 981454L
Authority
NO
Norway
Prior art keywords
fas antibodies
fas
antibodies
Prior art date
Application number
NO981454A
Other languages
English (en)
Norwegian (no)
Other versions
NO981454D0 (no
Inventor
Nobufusa Serizawa
Kimihisa Ichikawa
Jun Ohsumi
Masahiko Ohtsuki
Hideyuki Haruyama
Tohru Takahashi
Hiroko Yoshida
Akio Shiraishi
Shin Yonehara
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO981454D0 publication Critical patent/NO981454D0/no
Publication of NO981454L publication Critical patent/NO981454L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells
    • C12N5/163Animal cells one of the fusion partners being a B or a T lymphocyte
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO981454A 1997-04-01 1998-03-31 Anti-FAS-antistoffer NO981454L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8295397 1997-04-01
JP16908897 1997-06-25
JP27606497 1997-10-08

Publications (2)

Publication Number Publication Date
NO981454D0 NO981454D0 (no) 1998-03-31
NO981454L true NO981454L (no) 1998-10-02

Family

ID=27304060

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981454A NO981454L (no) 1997-04-01 1998-03-31 Anti-FAS-antistoffer

Country Status (17)

Country Link
EP (1) EP0909816A1 (cs)
KR (1) KR19980080993A (cs)
CN (1) CN1207395A (cs)
AR (1) AR010139A1 (cs)
AU (1) AU734758B2 (cs)
BR (1) BR9803296A (cs)
CA (1) CA2233783A1 (cs)
CZ (1) CZ294340B6 (cs)
HU (1) HUP9800744A3 (cs)
ID (1) ID20117A (cs)
IL (1) IL123888A0 (cs)
NO (1) NO981454L (cs)
NZ (1) NZ330095A (cs)
PL (1) PL325667A1 (cs)
RU (1) RU2212412C2 (cs)
TR (1) TR199800604A2 (cs)
TW (1) TW526205B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
JP4481489B2 (ja) * 1998-01-23 2010-06-16 エフ.ホフマン−ラ ロシュ アーゲー ヒトil−12に対する抗体
US6846637B1 (en) 1998-06-18 2005-01-25 Imed Ab Fas peptides and antibodies for modulating apoptosis
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
WO2000071160A1 (fr) 1999-05-24 2000-11-30 Sankyo Company, Limited Compositions medicinales contenant un anticorps anti-fas
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
WO2003022299A1 (en) * 2001-08-01 2003-03-20 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
ES2736165T3 (es) 2001-08-23 2019-12-26 Rsr Ltd Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
PT2311873T (pt) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
JP4560822B2 (ja) * 2008-08-01 2010-10-13 Axis株式会社 変形性関節症治療剤又は予防剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010448A1 (en) * 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
WO1994008454A1 (en) * 1992-10-14 1994-04-28 Uab Research Foundation Methods, compositions and screening assays relating to autoimmune disease
NZ275711A (en) * 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
NZ279108A (en) * 1994-01-07 1997-06-24 Immunex Corp Human fas (tgf/ngf receptor) ligand proteins coding sequences and production
AU6091496A (en) * 1995-06-07 1996-12-30 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
GB9523469D0 (en) * 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
CZ294340B6 (cs) 2004-12-15
TR199800604A3 (tr) 1999-10-21
PL325667A1 (en) 1998-10-12
KR19980080993A (ko) 1998-11-25
CN1207395A (zh) 1999-02-10
AR010139A1 (es) 2000-05-17
AU5970198A (en) 1998-10-08
IL123888A0 (en) 1998-10-30
HUP9800744A3 (en) 2001-04-28
ID20117A (id) 1998-10-01
CA2233783A1 (en) 1998-10-01
RU2212412C2 (ru) 2003-09-20
HU9800744D0 (en) 1998-05-28
HUP9800744A2 (hu) 1999-02-01
NZ330095A (en) 1998-12-23
BR9803296A (pt) 2000-01-11
CZ98598A3 (cs) 1998-10-14
AU734758B2 (en) 2001-06-21
EP0909816A1 (en) 1999-04-21
TW526205B (en) 2003-04-01
NO981454D0 (no) 1998-03-31
TR199800604A2 (xx) 1999-10-21

Similar Documents

Publication Publication Date Title
CY2005008I1 (el) Αντισωματα αντι - vegf
ATA93198A (de) Fluoxetinpellets
NO20001494L (no) Overligger
DE69826125D1 (de) Fixiergerät
ATA111897A (de) Kimme
NO981454L (no) Anti-FAS-antistoffer
ATE236897T1 (de) 3-benzylpiperidine
DE69825927D1 (de) Fixiereinrichtung
DK0862964T3 (da) Svejsebolte
DE69815048D1 (de) Kopiergerät
FR2770103B1 (fr) Bigoudi perfectionne
ATA86797A (de) Verschleissschuh
ID21138A (id) Teknologi film-tipis untuk head-drum
ATA46498A (de) Kunststoffgleitbahn
BR9701194A (pt) Hidrociclo
ZA982719B (en) Anti-fas antibodies
BR7702191U (pt) Flange paralelo
BR7700565U (pt) Overlap
BR9701096A (pt) Acertron iii
UA1662S (uk) Шрифт
ATA161897A (de) Zielfernrohr
ATA118697A (de) Zielfernrohr
ATE421585T1 (de) Motlinhomologe
FI973546A0 (fi) Moderplaot
BR1100556A (pt) Heterociclil-benzoilguanidinas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application